Analyst Ratings For Laboratory Corp
Portfolio Pulse from Benzinga Insights
Analyst ratings for Laboratory Corp (NYSE:LH) show a mix of bullish and bearish perspectives with a recent decline in the average 12-month price target from $253.00 to $242.4. The company, a major player in the clinical laboratory market, has seen adjustments in ratings and price targets by analysts from Truist Securities, Barclays, Baird, Leerink Partners, and Evercore ISI Group due to market conditions and company performance. Despite a notable market presence and revenue growth, Laboratory Corp's financial health indicators such as net margin and ROA are below industry benchmarks, while its ROE and debt management are positive.
April 26, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Laboratory Corp's mixed analyst ratings and a decrease in the average 12-month price target reflect cautious optimism. The company's strong market presence and revenue growth are positives, but concerns about financial health indicators could influence short-term stock performance.
The mixed analyst ratings and recent adjustments in price targets suggest a cautious but not overly negative outlook for Laboratory Corp. The company's significant market presence and recent revenue growth are likely to be viewed positively by investors, balancing concerns over its financial health indicators such as net margin and ROA. The overall impact on the stock price in the short term is likely to be neutral, as positive and negative factors may offset each other.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100